Skip to main content

Drug Interactions between probenecid and sodium phenylacetate

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

probenecid sodium phenylacetate

Applies to: probenecid and sodium phenylacetate

GENERALLY AVOID: Probenecid is known to inhibit the renal transport of many organic compounds, including aminohippuric acid, and may affect the renal excretion of phenylacetylglutamine and hippurate, the byproducts formed when sodium phenylacetate and sodium benzoate are administered for the treatment of acute hyperammonemia in patients with urea cycle disorders. Since phenylacetylglutamine and hippurate serve as vehicles to reduce waste nitrogen levels in such patients, adequate renal excretion is necessary to treat hyperammonemia and reduce the risk of glutamine-induced neurotoxicity.

MANAGEMENT: Although the interaction is theoretical and no data are available, it may be appropriate to avoid using probenecid during treatment of acute hyperammonemia in patients with urea cycle disorders due to the urgent nature of the condition. Uncontrolled hyperammonemia can rapidly result in brain damage or death.

References

  1. (2005) "Product Information. Ammonul (sodium benzoate-sodium phenylacetate)." Ucyclyd Pharma

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer